Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Impax Laboratories (IPXL) PT Raised to $20 at Cowen Following Strong 2Q
August 9, 2017 1:54 PM EDTCowen raised its price target on Impax Laboratories (NASDAQ: IPXL) to $20.00 (from $12.00) while maintaining a Market Perform rating.
Impax reported 2Q results that were above expectations as total revenues of $202MM were $6MM above the Street's estimate. The better revenues and better... More
Impax Laboratories (IPXL) Tops Q2 EPS by 4c
August 9, 2017 7:08 AM EDTImpax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.18, $0.04 better than the analyst estimate of $0.14. Revenue for the quarter came in at $202.1 million versus the consensus estimate of $195.62 million.
GUIDANCE:
Impax Laboratories sees FY2017 EPS of $0.55-$0.70, versus the consensus of... More
